The news said that the delegates of the two sessions are vaccinated

More than 5,000 delegates to the National People’s Congress (NPC) and members of the Chinese People’s Political Consultative Conference (CPPCC) who are attending this year’s National People’s Congress (NPC) have received the 2019 inactivated coronavirus disease (COVID-19) vaccine developed by Sinopharm, Yu Qingming, chairman of Sinopharm Holdings, who is also a deputy to the NPC, said today.

According to a report by the Central News Agency today, all 5,000 deputies and members of China’s two sessions were vaccinated. The report quoted Xinhua News Agency as saying that Yu Qingming, chairman of Sinopharm Holdings, which is also a deputy to the National People’s Congress, claimed that the vaccination of more than 5,000 delegates and members of the National People’s Congress “reflects the high level of trust in Sinopharm’s vaccine.

Yu Qingming claimed that the data from large-scale overseas clinical trials approved by various governments showed that the efficacy of Sinopharm’s vaccine reached 86%, with a neutralizing antibody conversion rate of over 99%, 100% effectiveness in preventing moderate cases and 100% effectiveness in preventing severe cases. Yu also said that Sinopharm is continuing to expand its annual vaccine production capacity, which will reach 3 billion doses in the future. The company is currently the world’s largest producer of COVID-19 vaccine and has supplied nearly 100 million doses both domestically and internationally, with more than 60 million doses administered and no serious adverse reactions associated with the vaccine detected to date.

According to Yu Qingming, after one year of continuous tracking of antibodies, all of them are still at a high level and have not decreased significantly, according to four party and government officials within China National Pharmaceutical Group who “tested themselves on the drug” in March 2020.

According to the Central News Agency, China now has four COVID-19 vaccines “conditionally approved” for marketing by the State Drug Administration, and emergency approval for clinical trials of 16 vaccines in five technical lines, six of which are in phase 3 clinical trials.